Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients

International Heart Journal

Volumn 51, Issue 3, 2010, Pages 188-192

  Nakano, Nobuyuki ^a   Ishimitsu, Toshihiko ^a   Takahashi, Toshiaki ^a   Inada, Hideki ^a   Okamura, Atsushi ^b   Ohba, Shuichi ^c   Matsuoka, Hiroaki ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Utsunomiya Chuoh Hospital   (Japan)

^c Ohba Clinic   (Japan)

Author keywords

Aldosterone; Efonidipine; Hemodialysis; Hypertension; Renal failure

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DIURETIC AGENT; EFONIDIPINE; RENIN; DIHYDROPYRIDINE DERIVATIVE; NITROPHENOL; ORGANOPHOSPHORUS COMPOUND;

ADULT; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE TITRATION; DRUG MECHANISM; FEMALE; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; AGED; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

AGED; ALDOSTERONE; AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CROSS-OVER STUDIES; DIHYDROPYRIDINES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM;

EID: 77954966895     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.188     Document Type: Article

References (42)

1. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008; 51: S1-320.
2. Japanese Society for Dialysis Therapy. An overview of dialysis treatment in Japan (as of Dec. 31, 2007). Nihon Toseki Igakkai Zasshi 2009; 42: 1-45.
3. Sarnak MJ., Levey AS., Schoolwerth AC., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69. (Review)
4. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003; 326: 15-24. (Review)
5. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-70. (Review)
6. Diamond JA, Phillips RA. Hypertensive heart disease. Hyper-tens Res 2005; 28: 191-202. (Review)
7. Ishimitsu T, Matsumoto N, Seta H, Yanaka H, Matsuoka H. Implication of angiotensin II as a cardiovascular risk factor in hemodialysis patients. J Jpn Coll Angiol 2007; 47: 383-89.
8. Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26: 461-8.
9. Mittal SK, Kowalski E, Trenkle J, et al. Prevalence of hypertension in a hemodialysis population. Clin Nephrol 1999; 51: 77-82.
10. Grekas D, Bamichas G, Bacharaki D, Goutzaridis N, Kasima-tis E, Tourkantonis A. Hypertension in chronic hemodialysis patients: current view on pathophysiology and treatment. Clin Nephrol 2000; 53: 164-8.
11. Tanaka H, Shigenobu K. Pathophysiological signifcance of T-type Ca2+ channels: T-type Ca2+ channels and drug development. J Pharmacol Sci 2005; 99: 214-20. (Review)
12. Imagawa K, Okayama S, Takaoka M, et al. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 2006; 47: 133-8.
13. Okayama S, Imagawa K, Naya N, et al. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 2006; 29: 493-7.
14. Conion PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Ne-phrol 1996; 7: 2658-63.
15. Zoccali C, Mallamaci F, Tripepi G, et al. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17: 1751-8.
16. Ishimitsu T, Nakano N, Sudo Y, et al. Predictive signifcance of blood pressure values for the incidence of cardiovascular events in chronic hemodialysis patients. Hypertens Res 2008; 31: 1703-9.
17. Yanaka H, Ishimitsu T, Takahashi M, Minami J, Ono H. Analysis of factors infuencing the left ventricular mass in chronic hemodialysis patients. J Jpn Soc Dial Ther 2002; 35: 1211-7.
18. Sato A, Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999; 12: 867-73.
19. Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on he-modialysis. Am J Nephrol 2007; 27: 159-63.
20. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786-96.
21. Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res 2006; 29: 253-60.
22. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256-61.
23. Ichihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losar-tan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005; 45: 866-74.
24. Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T. Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 1998; 31: 991-6.
25. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-90.
26. Ishimitsu T, Tsukada K, Ohta S, et al. Increased cardiovascular risk in long-term hemodialysis patients carrying deletion allele of ACE gene polymorphism. Am J Kidney Dis 2004; 44: 466-75.
27. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-9.
28. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-24.
29. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-9.
30. Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-6.
31. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihyper-tensive therapy. Kidney Int 1993; 44: 881-6.
32. Lopez-Gomez JM, Verde E, Perez-Garcia R. Blood pressure, left ventricular hypertrophy and long-term prognosis in hemo-dialysis patients. Kidney Int Suppl 1998; 68: S92-8. (Review)
33. Ozkahya M, Toz H, Qzerkan F, et al. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002; 15: 655-60.
34. Gunal AI, Karaca I, Aygen B, Yavuzkir M, Dogukan A, Celiker H. Strict fuid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study. J Int Med Res 2004; 32: 70-7.
35. Lins RL, Elseviers M, Rogiers P, et al. Importance of volume factors in dialysis related hypertension. Clin Nephrol 1997; 48: 29-33.
36. Ventura JE, Spósito M. Volume sensitivity of blood pressure in end-stage renal disease. Nephrol Dial Transplant 1997; 12: 485-91.
37. Ishimitsu T, Kameda T, Akashiba A, et al. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-6.
38. Tsutamoto T, Tanaka T, Nishiyama K, et al. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hyper-tens Res 2009; 32: 670-4.
39. Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cer-venka L, Mitchell KD. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999; 10: S266-72. (Review)
40. Delcayre C, Silvestre JS. Aldosterone and the heart: towards a physiological function? Cardiovasc Res 1999; 43: 7-12. (Review)
41. Davies E, MacKenzie SM. Extra-adrenal production of cor-ticosteroids. Clin Exp Pharmacol Physiol 2003; 30: 437-45. (Review)
42. Takai S, Jin D, Sakaguchi M, Miyazaki M. Signifcant target organs for hypertension and cardiac hypertrophy by angi-otensin-converting enzyme inhibitors. Hypertens Res 2004; 27: 213-9.